We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.75%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$80.1M
Cap. Flow
-$54.5M
Cap. Flow %
-1.47%
Top 10 Hldgs %
34.9%
Holding
147
New
53
Increased
24
Reduced
24
Closed
35

Top Buys

1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$134M
2
LLY icon
Eli Lilly
LLY
+$114M
3
HOLX
Hologic
HOLX
+$80.8M
4
NEO icon
NeoGenomics
NEO
+$60.6M
5
BIIB icon
Biogen
BIIB
+$55.7M

Top Sells

1
AZN icon
AstraZeneca
AZN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$103M
3
ABBV icon
AbbVie
ABBV
+$66.8M
4
MDT icon
Medtronic
MDT
+$61.4M
5
BHC icon
Bausch Health
BHC
+$60M

Sector Composition

1 Healthcare 95.4%
2 Technology 1.61%
3 Financials 0.67%
4 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$53.2M 1.44%
568,000
-13,000
-2% -$1.2M
BPMC
27
DELISTED
Blueprint Medicines
BPMC
$49.5M 1.34%
563,200
+17,200
+3% +$1.58M
NTRA icon
28
Natera
NTRA
$38.9B
$49.5M 1.34%
436,000
+40,400
+10% +$4.13M
SHC icon
29
Sotera Health
SHC
$5.06B
$46.3M 1.25%
1,910,000
+749,000
+65% +$18.4M
XLRN
30
DELISTED
Acceleron Pharma
XLRN
$45M 1.22%
358,500
+35,700
+11% +$4.5M
IDYA icon
31
IDEAYA Biosciences
IDYA
$3.47B
$43.4M 1.17%
2,070,000
+598,000
+41% +$12.3M
UTHR icon
32
United Therapeutics
UTHR
$22.7B
$42.4M 1.15%
+236,400
New +$45M
BBIO icon
33
BridgeBio Pharma
BBIO
$15.9B
$41M 1.11%
673,400
-141,700
-17% -$8.09M
ATEC icon
34
Alphatec Holdings
ATEC
$1.31B
$40.2M 1.09%
2,621,000
+287,000
+12% +$4.43M
TRIL
35
DELISTED
Trillium Therapeutics Inc.
TRIL
$39.8M 1.08%
4,105,000
+90,000
+2% +$847K
CYT
36
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$38.7M 1.05%
+1,808,394
New +$33.9M
CMPS
37
Compass Pathways
CMPS
$1.67B
$38.1M 1.03%
+1,000,000
New +$35.7M
CAH icon
38
Cardinal Health
CAH
$53.5B
$37.3M 1.01%
654,200
-808,800
-55% -$47.3M
KDMN
39
DELISTED
Kadmon Holdings, Inc.
KDMN
$36M 0.97%
9,294,600
-249,600
-3% -$968K
DVAX
40
DELISTED
Dynavax Technologies
DVAX
$33.5M 0.91%
3,400,000
-100,000
-3% -$909K
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$35.7B
$33.1M 0.89%
195,000
-232,969
-54% -$34.1M
INSM icon
42
Insmed
INSM
$23.5B
$32.7M 0.88%
+1,150,050
New +$34.1M
SPNE
43
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$31.3M 0.85%
+1,524,998
New +$31.4M
LFST icon
44
Lifestance Health
LFST
$4.42B
$30.6M 0.83%
+1,100,000
New +$29.1M
IPSC icon
45
Century Therapeutics
IPSC
$406M
$29.4M 0.8%
+1,003,522
New +$25.5M
LEGN icon
46
Legend Biotech
LEGN
$4.31B
$25.7M 0.69%
+625,000
New +$21.2M
IMCR icon
47
Immunocore
IMCR
$1.78B
$23.5M 0.63%
601,000
+51,000
+9% +$1.97M
ACET icon
48
Adicet Bio
ACET
$75.9M
$23.2M 0.63%
140,656
+1,281
+0.9% +$261K
ACAD icon
49
Acadia Pharmaceuticals
ACAD
$4.38B
$22.9M 0.62%
+940,000
New +$21.2M
LENZ
50
LENZ Therapeutics
LENZ
$162M
$22.6M 0.61%
+105,071
New +$18.3M
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
CM
Columbus Macro New Castle, Pennsylvania $936M AUM 12.9% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return

Avidity Partners Management's Q2 2021 Portfolio in Review

As of Q2 2021, Avidity Partners Management held 147 positions worth $3.7B, up 2.2% from $3.62B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Avidity Partners Management's Q2 2021 filing shows 53 new, 24 increased, 24 reduced and 35 closed positions. Its largest new stake was Eli Lilly: 565,500 shares worth $130M. The largest sale was AstraZeneca, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology and Financials.

  • Avidity Partners Management's largest Q2 2021 buy was Eli Lilly: 565,500 shares worth $130M.
  • Avidity Partners Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $134M increase.
  • Avidity Partners Management's biggest Q2 2021 reduction was AbbVie, cutting an estimated $66.8M.
  • Avidity Partners Management fully exited AstraZeneca in Q2 2021, selling an estimated $182M.
  • Avidity Partners Management's ten largest holdings make up 35% of its $3.7B portfolio in Q2 2021.
  • Avidity Partners Management opened 53 new positions and closed 35 in Q2 2021.
  • Avidity Partners Management's portfolio value rose 2.2% quarter-over-quarter to $3.7B.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.